Page 35 - Pharma Sector

Claims about dead people taking treatment under PM-JAY not true: Govt

Media reports claiming that Ayushman Bharat PM-JAY beneficiaries who are already dead are still on the system getting treatment are misleading, the health ministry said on Thursday. The ministry also said that mobile numbers have no role in deciding beneficiary eligibility. The ministry's remarks came in response to media reports that claimed that the Comptroller and Auditor General of India (CAG) has flagged that treatments have been booked for AB PM-JAY beneficiaries who have been declared dead on the system. The reports also claim that the same beneficiary had been found to avail treatment at two hospitals at the same time. "These media reports are completely misleading and ill-informed," the ministry said. The CAG report which contains results of the Performance Audit on Ayushman Bharat Pradhan Mantri - Jan Arogya Yojana (AB PM-JAY) covering the period September 2018-March 2021 was placed in parliament in the Monsoon Session of 2023, the ministry said in a statement. "It is ..

Aurobindo Pharma gets USFDA nod to make, market generic Icatibant injection

Aurobindo Pharma on Wednesday said its wholly-owned arm Eugia Pharma Specialities has received final approval from the US health regulator to manufacture and market generic Icatibant injection used in treatment of hereditary angioedema. The approval granted by the US Food & Drug Administration (USFDA) is for Icatibant injection of strength 30 mg/3 mL (10 mg/mL), single-dose pre-filled syringe, Aurobindo Pharma said in a regulatory filing. It is the bioequivalent and therapeutically equivalent of reference listed drug FIRAZYR (Icatibant injection) by Takeda Pharmaceuticals USA Inc, it added. "The product is being launched in September 2023," Aurobindo Pharma said. The approved product has an estimated market size of around USD 137 million for the 12 months ended June 2023, the company said citing IQVIA data.

AstraZeneca Pharma India Q1 PAT jumps over two-fold to Rs 53.86 cr

AstraZeneca Pharma India Ltd on Monday reported over two-fold rise in profit after tax at Rs 53.86 crore for the first quarter ended June 30, 2023. The company had posted a profit after tax of Rs 20.15 crore in the same quarter last fiscal, AstraZeneca Pharma India said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 295.46 crore, as against Rs 232.33 crore in the year-ago period, it added. Total expenses were higher at Rs 232.17 crore, as against Rs 209.14 crore, the company said.

Abbott India posts 41% rise in Q1 profit at Rs 29 crore on strong sales

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales

DSCO issues show cause notices to 143 pharma firms after inspections

The Central Drugs Standard Control Organisation along with state licensing authorities has conducted risk-based inspections of 162 pharmaceutical firms and issued show cause notices in 143 cases, Union Health Minister Mansukh Mandaviya said on Tuesday. In a written reply to a question in Rajya Sabha, he said stop production order has been issued in 40 cases, cancellation and suspension of product/section licenses in 66 cases, issuance of warning letter in 21 cases and in one case, an FIR has been lodged and three persons have been arrested as per the provisions of the Drugs Rules, 1945. He also said that the Directorate General of Foreign Trade, Department of Commerce, Ministry of Commerce and Industry issued a notification on May 22 for amendment in export policy of cough syrups, making it compulsory for cough syrup manufacturers to get certificate of analysis from a government-approved laboratory before exporting their products with effect from June 1. Accordingly, more than 900 .

Fierce competition among new drug brands for share of India market

The competitive intensity is high between brands, at a time when volume growth in the domestic pharma market is on a slow lane

India has started manufacturing 38 APIs in past 1.5 years: Mandaviya

India has started manufacturing 38 active pharmaceutical ingredients, or APIs, in the last one and a half years on which it was import-dependent, under the production-linked incentive (PLI) scheme for the sector, Union Health Minister Mansukh Mandaviya said here Saturday. Mandaviya said that the 2017 border standoff with China at Doklam triggered India to rethink its self-reliant strategy regarding active pharma components as it was dependent on just one country for the import of 95 per cent of APIs for the formulation industry. The health minister was speaking at the inaugural event of the Healthcare Summit organised at the Indian Institute of Management Ahmedabad (IIMA). Through the PLI scheme, we tried to ensure that the country does not have to import 54 APIs from abroad and our formulation industry gets APIs domestically. I am happy to share that in just a year and a half, India has started manufacturing 38 APIs, which is an example of Atmanirbhar Bharat, he said. The governme

Jhunjhunwala-backed Concord Biotech IPO opens today: What do analysts say?

Concord Biotech IPO: The stock is commanding a 20 per cent premium in the grey market, as per ipowatch.com

CDSCO orders Riemann Labs to stop making cough syrup linked to deaths

The Central Drugs Standard Control Organisation (CDSCO) in coordination with State Drug Controllers of Madhya Pradesh has directed pharma firm Riemann Labs to halt manufacturing of its cough syrup that was linked to deaths of children in Cameroon. "In the case of Cameroon, a joint inspection was conducted by CDSCO, sub-zone Indore with SLA, Madhya Pradesh at M/s Riemann Labs, Indore and based on the findings the State Drugs Controller MP has directed the firm to stop the manufacturing activities," Minister of State (MoS) for Health Bharati Pravin Pawar said in a written reply in Rajya Sabha on Tuesday. The World Health Organization (WHO) had on July 19 issued an alert regarding cough syrup supplied in Cameroon stating an analysis has found that the product contained "unacceptable amounts of diethylene glycol as contaminants." The makers of Naturcold listed paracetamol, phenylephrine hydrochloride, and chlorpheniramine maleate as active ingredients, and a combination of these three i

Sun Pharma Q1 profit may be weighed by weak US generic sales and Taro nos

Sun Pharma Q1 results: The company's Q1 net profit could dip fractionally by 0.15 per cent to Rs 2,058 crore against Rs 2,061 crore reported a year ago

Lupin gets USFDA approval to market generic skin treatment medication

Lupin on Wednesday said its American subsidiary has received an approval from the US health regulator to market a generic product used for treatment of skin issues. New Jersey-based Novel Laboratories Inc has received the approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin said in a statement. The product is the generic version of Hill Dermaceuticals Inc's Derma-Smoothe/FS Topical Oil. Lupin said the product will be manufactured at its Somerset facility in the US. As per the IQVIA MAT March 2023 data, Fluocinolone Acetonide Topical Oil had estimated annual sales of USD 9 million in the US. Lupin shares were trading 0.67 per cent down at Rs 981.65 apiece on the BSE.

India finds 'violations' at cough syrup maker linked to Cameroon deaths

Authorities have stepped up scrutiny of drugmakers after some cough syrups made in India were linked to deaths of dozens of children overseas

Global abortion pill provider buys from Indian firm with bad quality record

More than 30 samples of drugs made by Delhi-based Synokem Pharmaceuticals Ltd have failed quality tests conducted by Indian regulators

CVS Health Corp to cut 5,000 jobs amid shift away from retail focus

None of the job losses will impact customer-facing positions in stores, pharmacies, clinics or customer services centers, a spokesman for the company said

Glenmark Pharmaceuticals gets USFDA nod to market generic diabetes drug

Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in the American market. The company has received final approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets (2.5 mg and 5 mg), the generic version of AstraZeneca's Onglyza1 tablets, the Mumbai-based drug maker said in a statement. According to IQVIATM sales data, for the 12-month period ending June 2023, the Onglyza tablets (2.5 mg and 5 mg) achieved annual sales of around USD 100.7 million. Glenmark said its current portfolio now consists of 184 products authorized for distribution in the US market and 49 abbreviated new drug applications (ANDAs) are pending approval with the US FDA.

Top headline: Govt hikes windfall tax on petroleum crude, Nuh violence

Business Standard brings you the top headlines at this hour

In-home cardio care: Lupin Digital, American College of Cardiology tie up

The aim is to give patients and healthcare providers tools to manage heart diseases at home and reduce rehospitalisation

China eyes next pandemic in push for new medical emergency facilities

The facilities will be used for tourism, recreation and healthcare in normal times. During emergencies, they will serve as medical treatment and quarantine centers

WHO seeks help from India in latest toxic syrup-deaths case in Cameroon

The alert about Naturcold is the latest of several similar warnings issued in recent months about contaminated cough syrups sold worldwide

Lupin gets thumbs up from USFDA to market generic medication in US

Drug firm Lupin on Friday said its unit has received approval from the US health regulator to market a medication to treat various disorders like schizophrenia. The company's Somerset-based wholly-owned subsidiary Lupin Inc has received approval from the US Food and Drug Administration (USFDA) for Chlorpromazine Hydrochloride tablets, Lupin said in a statement. The Mumbai-based drug maker's product is the generic version of Upsher-Smith Laboratories, LLC's product. As per IQVIA MAT data, Chlorpromazine Hydrochloride Tablets had an estimated annual sale of USD 45 million in the US.